ORAI1 and cancer: In contrast, cancer samples expressing Orai1 dramatically decreased in CRPC-adeno (4% of positive cases) and in CRPC-NE (21% of positive cases) when compared to CLC (64% of positive cases) (p < 0.0001 and 0.004, respectively).